Park Ha Biological Enters Underwriting Agreement for Share Offering
Ticker: BYAH · Form: 6-K · Filed: Dec 30, 2024 · CIK: 1986247
Sentiment: neutral
Topics: underwriting-agreement, public-offering, capital-raise
TL;DR
Park Ha Biological signed a deal with Dawson James Securities for a share offering. Details TBD.
AI Summary
On December 26, 2024, Park Ha Biological Technology Co., Ltd. entered into an underwriting agreement with Dawson James Securities, Inc. This agreement pertains to the company's proposed public offering of its ordinary shares. The filing does not specify the number of shares or the price range for this offering.
Why It Matters
This agreement signals Park Ha Biological's intention to raise capital through a public offering, which could impact its financial structure and future growth prospects.
Risk Assessment
Risk Level: medium — The filing indicates a planned share offering, which carries inherent market and execution risks for the company and investors.
Key Players & Entities
- Park Ha Biological Technology Co., Ltd. (company) — The company entering into the underwriting agreement.
- Dawson James Securities, Inc. (company) — The representative of the underwriters in the agreement.
- December 26, 2024 (date) — The date the underwriting agreement was entered into.
FAQ
What is the purpose of the underwriting agreement entered into by Park Ha Biological Technology Co., Ltd.?
The underwriting agreement was entered into for a proposed public offering of the Company's ordinary shares.
Who is the underwriter for Park Ha Biological Technology Co., Ltd.'s proposed share offering?
Dawson James Securities, Inc. is the representative of the underwriters named in the agreement.
On what date was the underwriting agreement signed?
The underwriting agreement was entered into on December 26, 2024.
What type of company is Park Ha Biological Technology Co., Ltd.?
Park Ha Biological Technology Co., Ltd. is a Cayman Islands exempted company.
Does the filing specify the number of shares or the price for the public offering?
No, the filing does not specify the number of shares or the price range for the proposed public offering.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-12-30 17:27:49
Key Financial Figures
- $0.00002 — of 1,200,000 ordinary shares, par value $0.00002 per share (the “Shares”), a
- $4.00 — uo;Shares”), at offering price of $4.00 per share. The Company has also granted
Filing Documents
- ea0226324-6k_parkha.htm (6-K) — 13KB
- ea022632401ex1-1_parkha.htm (EX-1.1) — 226KB
- ea022632401ex99-1_parkha.htm (EX-99.1) — 10KB
- ea022632401ex99-2_parkha.htm (EX-99.2) — 13KB
- 0001213900-24-113560.txt ( ) — 262KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Park Ha Biological Technology Co., Ltd. Date: December 30, 2024 By: /s/ Xiaoqiu Zhang Name: Xiaoqiu Zhang Title: Chief Executive Officer, Chairperson of the Board of Directors 2 EXHIBIT INDEX Exhibit No. Description 1.1 Underwriting Agreement dated December 26, 2024 between the Company and Dawson James Securities, Inc. 99.1 Press Release on Pricing of the Company’s Initial Public Offering 99.2 Press Release on Closing of the Company’s Initial Public Offering 3